Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, multi-center, observer blind, controlled, randomized study to compare the immunogenicity and safety of the concomitant administration of a combined tetanus, reduced diphtheria, and acellular pertussis (Tdap) vaccine and Chiron meningococcal ACWY conjugate vaccine, with either one dose of acellular pertussis (Tdap) vaccine, or one dose of Chiron meningococcal ACWY conjugate vaccine, in healthy subjects aged 11-25 years.

Next Previous
Trial Profile

A phase 3, multi-center, observer blind, controlled, randomized study to compare the immunogenicity and safety of the concomitant administration of a combined tetanus, reduced diphtheria, and acellular pertussis (Tdap) vaccine and Chiron meningococcal ACWY conjugate vaccine, with either one dose of acellular pertussis (Tdap) vaccine, or one dose of Chiron meningococcal ACWY conjugate vaccine, in healthy subjects aged 11-25 years.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DTaP vaccine (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Diphtheria; Meningococcal infections; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Chiron Corporation; Novartis

    • Most Recent Events

    • 28 Apr 2008 Interim results will be reported at PAS 2008, according to a Novartis media release.
    • 31 Jan 2008 Status changed from in progress to completed according to ClinicalTrials.gov
    • 05 Jul 2007 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top